Summary of "Phase 2B trial for PP405 leaked (The study Pelage DOESN'T want you to see)"

Concise summary

A leaked report from a completed Phase 2B (3‑month extension for a total of 6 months) trial of topical “PP405” (Polage Pharmaceuticals) shows the placebo/vehicle outperformed the active treatment. The leak contradicts earlier optimistic hype and suggests PP405 is unlikely to be a major hair‑regrowth breakthrough.

Study design and key results (Phase 2B extension)

Design
- Double‑blind extension of the original Phase 2A trial (initial 3 months + 3‑month extension = 6 months total).
- Participants remained blinded and continued on the same topical (active or placebo) as in Phase 2A.
Subjects
- 66 total participants: 40 on topical PP405, 26 on topical placebo.
Primary endpoint
- Change in total hair counts (hairs per cm²).
Results
- PP405 group: +5.1 hairs/cm² at 6 months (p = 0.049) — marginally significant versus baseline.
- Placebo group: +33.7 hairs/cm² at 6 months (p < 0.00001) — large within‑group increase.
- Between‑group comparison: placebo exceeded PP405 by 28.4 hairs/cm² (p < 1e‑7) — highly significant favoring placebo.
- Note: the published slide/table from Polage was redacted; the presenter’s talk at the conference reportedly rehashed earlier Phase 2A material and omitted these Phase 2B details.

Scientific concepts, observations, and implications

Trial structure
- A Phase 2A followed by a blinded Phase 2B extension was used to assess longer‑term effects.
Placebo/vehicle effects
- The large hair‑count increase in the placebo arm suggests a potent vehicle/placebo effect or other non‑drug factors affecting hair counts in this study.
Statistics and interpretation
- The active arm showed a small absolute improvement with a borderline p‑value versus baseline, while the placebo arm showed a much stronger response, producing a highly significant advantage for placebo in between‑group comparison.
- This pattern implies either PP405 is ineffective relative to vehicle or, less likely but possible, PP405 may inhibit the vehicle’s beneficial effect.
Verification efforts
- Investigators reportedly tested the placebo vehicle for contamination (e.g., minoxidil/finasteride) and reported finding nothing unusual — the placebo was said to be the same vehicle without PP405.
Practical implication
- Presenters emphasized that established, evidence‑backed therapies (5α‑reductase inhibitors such as finasteride/dutasteride and topical minoxidil) remain the reliable standard of care. Pipeline drugs should not replace proven treatments without robust positive data.

Other trial and industry notes

The presenter at the conference had previously presented Phase 2A results; Phase 2B results were tightly guarded by Polage and later leaked.
Community speculation included ideas of industrial sabotage, but reported analyses did not support contamination of the vehicle.
Anecdotal/rumored company reaction: severe disappointment on unblinding; tongue‑in‑cheek claims that Polage might reposition or rename their vehicle in future trials (unverified).
Planned next steps: Polage reportedly plans further trials (Phase 3 was suggested), but specifics and official presentation dates were not provided in the leak.

Limitations and caveats

The Polage slide was redacted; the Phase 2B account is based on a leak and an informant (a co‑investigator who requested anonymity).
Interpretation depends on accurate reporting of the leaked numbers. Until Polage or a peer‑reviewed report publishes full data, these results should be treated cautiously.

Researchers and sources featured

Dr. Arash Mostaghimi — presenter of Phase 2A results (affiliated with Harvard as referenced in the video).
Unnamed Harvard co‑investigator / whistleblower (requested anonymity).
Polage Pharmaceuticals — developer of PP405.
Amplifica — company mentioned (developing AMP‑303; referenced in speculation).
American Academy of Dermatology (AAD) — venue of the presentation (annual dermatology meeting).
Reddit and online patient/community discussions — community sources referenced.